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Background: Idiopathic pulmonary fibrosis (IPF) is reportedly associated with an increased risk
of lung cancer. However, few studies have explored whether IPF affects the long-term survival
of lung cancer patients. The primary goal of this study was to evaluate the characteristics of
lung cancer in IPF patients and impact of IPF on lung cancer survival.
Methods: Seventy IPF patients with histologically proven lung cancer were identified through a
search of the Seoul National University Bundang Hospital database between 2003 and 2012. Of
these, 33 patients who had undergone surgery were matched with 66 patients who had lung
cancer without IPF. Matched variables included age, sex, histologic type, and lung cancer
stage.
Results: Of the 70 subjects, 94% were male, and the mean age was 70 years (range, 46e90). In
total, 81% of the tumors were located in the lung periphery, and 56% were in the lower lobe.
The majority of cancers (70%) were observed in the fibrotic area on chest computedation of idiopathic pulmonary fibrosis; ARDS, acute respiratory distress syndrome; COPD, chronic
diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced
ary fibrosis; IPF-LC, idiopathic pulmonary fibrosis and lung cancer; SqCC, squamous cell carcinoma.
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1550 T. Lee et al.tomography scans. The most frequent histologic type was squamous cell carcinoma (40%).
Among surgically treated patients (33 cases and 66 controls), the 5-year survival rates were
38% for lung cancer patients with IPF and 73% for those without IPF (p Z 0.001).
Conclusions: Squamous cell carcinoma was the most common type of lung cancer in IPF pa-
tients. IPF reduced the survival of surgically treated lung cancer patients regardless of age,
sex, histologic type, and/or lung cancer stage.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is believed to be an in-
dependent risk factor for lung cancer [1e3]. Previous
studies have highlighted the clinical risk factors associated
with lung cancer development in IPF patients and examined
the clinical characteristics and survival of patients having
both IPF and lung cancer (IPF-LC) [4e8]. All studies
consistently show that elderly male IPF patients with a
history of smoking are more likely to develop lung cancer
[4e6]. However, tumor location in IPF-LC patients differs
among studies [4e8]. Furthermore, there is no consensus
regarding the most prevalent histologic type of IPF-LC
[5,6,9e11].
Recently, a change in the epidemiology of lung cancer
has been reported with adenocarcinoma being the most
common histologic type and squamous cell carcinoma
(SqCC) as the second [12,13]. Accordingly, the epidemi-
ology of lung cancer in IPF patients is expected to change.
However, most studies examining the characteristics of
lung cancer in IPF patients were conducted several decades
ago. In addition, the definition of IPF as well as the man-
agement and staging of lung cancer have also changed
significantly. Thus, a new evaluation of lung cancer char-
acteristics in IPF patients is much needed.
On the other hand, only a few studies have assessed the
long-term survival of IPF-LC patients [7,8,14,15]. In these
studies, IPF appeared to influence survival. However, these
previous investigations often have limitations, including a
lack of adjustment for co-variables [7,14] and a limited
number of early-staged subjects enrolled [8]. Therefore,
whether IPF independently affects long-term survival of
lung cancer patients remains inconclusive based on previ-
ously reported data.
In the present study, we evaluated clinical characteris-
tics of IPF-LC and aimed to assess the independent impact
of IPF on the long-term survival of patients with surgically
resectable lung cancer (stages IeIIIA).Materials and methods
Study population
Patients diagnosed with both IPF and histologically proven
lung cancer at Seoul National University Bundang Hospital,
a tertiary teaching hospital, from May 2003 to April 2012
were retrospectively identified. IPF was diagnosed accord-
ing to the 2011 consensus of the American Thoracic Society(ATS), the European Respiratory Society (ERS), the Japa-
nese Respiratory Society, and the Latin American Thoracic
Association [16]. A total of 70 patients with IPF-LC were
initially selected.
Caseecontrol study and matching
Of the 70 patients with IPF-LC, 36 who had undergone
surgeries were designated as the case group. The control
group included patients with lung cancer without IPF who
were randomly selected from the lung cancer database
(n Z 1374) and had also undergone surgeries during the
same period (May 2003 to April 2012) at Seoul National
University Bundang Hospital. Two control subjects were
selected for each case by matching patients’ age (1 year),
sex, cancer histologic type, and pathologic staging. In 3
cases, matching was impossible due to insufficient data.
Thus, 33 cases and 66 controls were evaluated.
Study design
The clinical data of 70 IPF-LC patients were thoroughly
reviewed, including all patient characteristics at the time
of cancer diagnosis. Demographic data (age, sex, and
smoking status/amount) and pulmonary function test re-
sults (forced vital capacity [FVC], forced expiratory volume
in 1 s [FEV1], and diffusing capacity of the lung for carbon
monoxide [DLCO]) were examined. Chest computed to-
mography was also evaluated for tumor location (lobe,
fibrotic/non-fibrotic area, and peripheral/central area).
Additionally, information regarding histologic type, clinical
staging, and pathologic staging (for those who underwent
surgery) of lung cancer was meticulously reviewed. Central
lung cancer was defined as those (1) with an endobronchial
lesion observable on bronchoscopy or (2) located > 3 cm
apart from the pleura [11]. Staging of lung cancer was
performed in accordance with the International Association
for the Study of Lung Cancer’s 7th TNM proposal report
[17].
Patients’ survival, time to relapse, and cause of death
were investigated in matched cases (n Z 33) and controls
(nZ 66). The final status of each patient was determined in
May 2012 on the basis of either his/her most recent clinical
assessment or a telephone interview. The cause of death
was defined as follows: cancer-related death meaning
death due to cancer progression, and respiratory death
being death due to pneumonia, acute respiratory distress
syndrome (ARDS), or acute exacerbation of IPF (AEIPF). This
study was approved by the Institutional Review Board and
Table 1 Baseline characteristics of lung cancer in IPF.
n Z 70
Sex, male 66 (94)
Lung cancer in patients with IPF 1551Ethics Committee of Seoul National University Bundang
Hospital (IRB number: B1301-188-112) and the informed
consent requirement was waived due to the retrospective
study design.Age, year 70  7
Smoking status
Current smoker 26 (37)
Former-smoker 40 (57)
Never-smoker 4 (6)
Smoking amount, pack-year 41  20
Diagnosis of IPF
Clinically 48 (69)
Lung biopsy 22 (31)
Time of IPF diagnosis
At the time of lung cancer diagnosis 38 (54)
Before lung cancer diagnosis 32 (46)Statistical analysis
Fisher’s exact test and the chi-square (c2) test were used to
compare categorical variables, whereas an independent
Student’s t-test was for comparison of continuous vari-
ables. Survival and relapse were estimated using the
KaplaneMeier method and compared by the log-rank test.
All statistical analyses were performed using SPSS 18.0
(Chicago, IL, USA). A p-value of <0.05 was considered
statistically significant.Duration of IPF diagnosis, month 41  36
Treatment of IPF
N-acetylcysteine 3 (4.2)
Corticosteroid 6 (8.5)
Azathioprine 2 (2.8)
Pirfenidone 0
FEV1/FVC 0.71  0.09
FEV1, predicted % 87  22
FVC, predicted % 84  20
DLCO, predicted % 70  18
Combined emphysema 27 (39)
Histologic type
Squamous cell carcinoma 28 (40)
Adenocarcinoma, 21 (30)
Large cell carcinoma 3 (4)
NSCLC, NOS 10 (14)
SCLC 8 (12)
Data were presented by mean  SD or n (%).
Abbreviations: IPF, idiopathic pulmonary fibrosis; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; DLCO,
diffusing capacity of the lung for carbon monoxide; NSCLC, non-
small cell lung cancer; NOS, not otherwise specified; SCLC,
small cell lung cancer.Results
Baseline characteristics
The baseline characteristics of all 70 IPF-LC patients are
shown in Table 1. IPF was clinically diagnosed according to
the ATS/ERS guideline in 69% of all patients. The diagnosis
of IPF preceded that of lung cancer in 46% of patients with a
mean lapse time of 41 months. Six patients were treated
with corticosteroid and three received N-acetylcysteine.
The mean post-bronchodilator FEV1/FVC ratio was 0.71.
Twenty-seven patients (39%) had chronic obstructive pul-
monary disease (COPD) defined by a post-bronchodilator
FEV1/FVC ratio of <0.7. Since most patients were
smokers, significant emphysema was observed in 39% of all
IPF patients, resulting in combined pulmonary fibrosis and
emphysema (CPFE).
SqCC was the most common type of lung cancer (40%),
followed by adenocarcinoma (Table 1). At the time of
diagnosis, early-stage lung cancer was more common than
advanced-stage disease (for non-small cell lung cancer:
stage I, 41%; stage II, 21%; stage III, 14%, and stage IV, 24%)
(Table 2). Tumors were more frequently observed in the
lower lobes (55%) and lung periphery (81%), which usually
adjoined the fibrous area (70%) (Table 3).Table 2 Clinical stages of lung cancer in IPF patients.
NSCLC (n Z 62)
IA, n (%) 9 (15)
IB, n (%) 16 (26)
IIA, n (%) 10 (16)
IIB, n (%) 3 (5)
IIIA, n (%) 4 (6)
IIIB, n (%) 5 (8)
IV, n (%) 15 (24)
SCLC (n Z 8)
LD, n (%) 4 (50)
ED, n (%) 4 (50)
Abbreviations: NSCLC, non-small cell lung cancer; SCLC, small
cell lung cancer; LD, limited disease; ED, extensive disease.Comparison of lung cancer between patients with
IPF-LC and those with lung cancer only
In the matched caseecontrol study of surgically treated
patients, the median follow-up time was 21 months (range,
0e95 months) for IPF-LC patients and 33 months (range,
1e86 months) for those with lung cancer only. Among the
33 IPF-LC patients, IPF had been discovered at the time of
lung cancer diagnosis in 19 patients. Patients with IPF-LC
were more likely to have a higher FEV1/FVC ratio, lower
FVC, lower DLCO and higher carcinoembryonic antigen
(CEA) levels than those with lung cancer only. In addition,
the primary mass was more likely to be localized in the
peripheral lower lung (periphery: 100% vs. 67%, p < 0.001;
lower lobes: 60% vs. 30%, p Z 0.012) (Table 4). Patients
with IPF-LC were more likely to have sublobar resection and
shorter anesthesia time. However, mechanical ventilator
Table 4 Comparison between lung cancer in IPF and
cancer only patients.
IPF and
cancer
(n Z 33)
Cancer
only
(n Z 66)
p-Value
Sexa, male 31 (94) 62 (94) 1.000
Agea, year 67  8 66  7 0.985
Body mass index,
Kg/m2
23.5  2.5 23.1  2.7 0.505
Smoking status
Current smoker 13 (39) 30 (45) 0.089
Former-smoker 18 (55) 23 (35)
Never-smoker 2 (6) 13 (20)
FEV1/FVC 0.72  0.08 0.65  0.11 0.001
FEV1, predicted % 95  15 93  22 0.669
FVC, predicted % 92  14 101  19 0.014
DLCO, predicted % 76  17 110  27 <0.001
CEA, ng/ml 5.9  4.7 3.2  4.6 0.009
Preoperative PaO2,
mmHg
84.0  22.9 87.4  11.9 0.436
Histologic typea
Squamous cell
carcinoma
17 (52) 34 (52) 1.000
Adenocarcinoma 16 (48) 32 (48)
Pathologic stagea
IA 9 (27) 18 (27) 1.000
IB 14 (42) 28 (42)
IIA 6 (18) 12 (18)
IIB 2 (6) 4 (6)
IIIA 2 (6) 4 (6)
IIIB 0 (0) 0 (0)
IV 0 (0) 0 (0)
Location of cancer (lobe)
RUL 4 (12) 22 (33) 0.012
LUL 6 (18) 22 (33)
RML 3 (9) 2 (3)
RLL 11 (33) 12 (18)
LLL 9 (27) 8 (12)
Location of cancer (area)
Periphery 33 (100) 44 (67) <0.001
Central 0 (0) 22 (33)
Anesthesia time, min 219.5  88.0 269.5  71.3 0.003
Operation type
VATS 15 (45.5) 24 (36.4) 0.383
Sublobar resection 11 (33.3) 6 (9.1) 0.003
Length of
hospitalization,
days
12.6  15.3 10.5  12.5 0.474
Postoperative
pulmonary
complications
9 (27.3) 12 (18.2) 0.297
Mechanical ventilator
care
5 (15.2) 1 (1.5) 0.007
Death 15 (46) 13 (20) 0.007
Data were presented by mean  SD or n (%).
Abbreviations: CEA, carinoembryonic antigen; VATS, video-
assisted thoracoscopic surgery See Tables 1e3 legends for
expansion of other abbreviations.
a Age, sex, histologic type and pathologic stages were
matched variables.
Table 3 Location of lung cancer in IPF patients.
n Z 70
Lobe of primary mass
RUL, n (%) 17 (24)
LUL, n (%) 11 (16)
RML, n (%) 3 (4)
RLL, n (%) 22 (31)
LLL, n (%) 17 (24)
Relation with fibrotic area
Abutting the fibrous area, n (%) 49 (70)
Apart from the fibrous area, n (%) 21 (30)
Central vs. peripheral area
Periphery of the lung, n (%) 57 (81)
Central of the lung, n (%) 13 (19)
Abbreviations: RUL, right upper lobe; LUL, left upper lobe; RML,
right middle lobe; RLL, right lower lobe; LLL, left lower lobe.
1552 T. Lee et al.care and deaths were more common in IPF-LC compared to
lung cancer only patients.
Survival of IPF-LC patients
Survival time was significantly shorter in patients with IPF-
LC (5-year survival rate: 37.5% vs. 72.5%, p Z 0.001).
Although such a trend was observed in surgically treated
patients of all disease stages (I, II, IIIA) (Fig. 1), the survival
difference was not statistically significant in stage IIIA pa-
tients owing to the small sample size. Relapse-free survival
duration was also significantly shorter in patients with IPF-
LC than in those with lung cancer only (5-year relapse-free
survival rate: 46.9% vs. 66.8%, p Z 0.014) (Fig. 2). During
the follow-up period, death occurred in 15 of 33 (46%) IPF-
LC patients and 13 of 66 (20%) patients with lung cancer
only (p Z 0.007). The incidence of respiratory death was
significantly higher in the IPF-LC group (7/33 [21%] vs. 2/66
[3%], p Z 0.003) (Table 5). Of the 7 respiratory deaths in
IPF-LC patients, 2 occurred postoperatively (postoperative
days: 7 and 37, respectively). No postoperative deaths were
observed among patients with lung cancer only.
Although patients with respiratory death had a tendency
to show lower preoperative PaO2 and more SqCC types than
survivors, those were not statistically significant (Table 6).
Baseline pulmonary function, smoking status, operative
factors were not different between the survivors and pa-
tients dying from respiratory causes (Table 6).
Discussion
In the present study, we demonstrated that IPF was an in-
dependent prognostic factor of survival in surgically treated
lung cancer patients, regardless of age, sex, histologic
type, and/or disease stage. IPF was also associated with
early cancer relapse and respiratory death (i.e., death from
pneumonia, ARDS, or AEIPF). Although the most common
type of lung cancer in Korea is adenocarcinoma [12,13], we
found that SqCC was the most frequent histologic type in
IPF-LC patients, indicating a different distribution of lung
cancer histologic types among IPF-LC patients than that of
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Figure 1 Survival curves for the caseecontrol study of surgically treated patients. (A) All surgically treated patients; (B) Patients
with pathologic stage I; (C) Patients with pathologic stage II; (D) Patients with pathologic stage IIIA Abbreviation: 5YSR, 5 year-
survival rate.
Lung cancer in patients with IPF 1553the general population. Additionally, unlike reported re-
sults from the previous Korean study [6], we observed that
lung cancer was localized to the periphery, lower lobe, and
fibrotic area of the lungs in our patient cohort. Our finding
was similar to reports from other countries [4,5,7,8].Relapse-free survival after surgery: all patients
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Figure 2 Relapse-free survival curve for the caseecontrol
study Abbreviation: 5YRFSR, 5 year-relapse free survival rate.IPF may be considered an independent risk factor for
lung cancer [1e3], and a recent position paper identified
lung cancer as one of the comorbidities of IPF [16]. Sub-
sequent studies established predisposing factors in IPF pa-
tients that were associated with lung cancer development,
such as old age, male sex, and smoking history [4,5,7,8].
However, an in-depth evaluation of IPF’s effect on the
survival of lung cancer patients with lung cancer is lacking,Table 5 Causes of death in surgically treated lung cancer
patients.
IPF and
cancer
(n Z 33)
Cancer only
(n Z 66)
p-Value
Respiratory death,
n (%)
7 (21) 2 (3) 0.003
Cancer-related
death, n (%)
7 (21) 7 (11) 0.153
Othersa, n (%) 1 (3) 4 (6) 0.516
a Unknown Z 2, Sudden cardiac death Z 2, traffic
accident Z 1.
Table 6 Comparison of survivors and patients with respi-
ratory death in surgically treated lung cancer patients with
IPF.
Respiratory
death
(n Z 7)
Survivors
(n Z 18)
p-Value
Sex, male 7 (100) 16 (89) 1.000
Age, year 65  9 69  7 0.301
Body mass index,
Kg/m2
23.6  2.9 23.9  2.7 0.774
Smoking status
Current smoker 2 (29) 7 (39) 0.761
Former-smoker 5 (71) 10 (56)
Never-smoker 0 (0) 1 (5)
FEV1/FVC 0.75  0.06 0.70  0.09 0.171
FEV1, predicted % 96  18 95  14 0.909
FVC, predicted % 89  17 93  15 0.572
DLCO, predicted % 71  22 76  18 0.564
CEA, ng/ml 4.5  1.5 4.9  3.5 0.793
Preoperative PaO2,
mmHg
78.7  16.8 92.5  17.7 0.090
Histologic type
Squamous cell
carcinoma
6 (86) 7 (39) 0.073
Adenocarcinoma 1 (14) 11 (61)
Pathologic stage
IA 2 (29) 6 (33) 0.245
IB 2 (29) 9 (50)
IIA 3 (42) 1 (5)
IIB 0 (0) 1 (5)
IIIA 0 (0) 1 (5)
IIIB 0 (0) 0 (0)
IV 0 (0) 0 (0)
Location of cancer (lobe)
RUL 0 (0) 2 (11) 0.361
LUL 0 (0) 4 (22)
RML 2 (29) 1 (6)
RLL 2 (29) 6 (33)
LLL 3 (42) 5 (28)
Anesthesia time,
min
236.4  102.0 211.1  90.4 0.550
Operation type
VATS 3 (42.9) 9 (50.0) 0.748
Sublobar
resection
2 (28.6) 7 (38.9) 0.629
Data were presented by mean  SD or n (%).
Abbreviations: See Table 4 legends for expansion of other
abbreviations.
1554 T. Lee et al.and studies on the clinical characteristics of IPF-LC have
reported conflicting results. In the present matched case-
econtrol study, we evaluated the independent impact of
IPF on the long-term survival of patients with surgically
resected lung cancer (stages IeIIIA) and assessed various
clinical characteristics of IPF-LC conflicting published data.
Furthermore, in order to provide meaningful information
relevant to the clinical practice, the studied lung cancer
cases were staged according to a recently revised standard(International Association for the Study of Lung Cancer’s
7th TNM proposal report) [17].
Our results indicated a trend for reduced survival in
surgically treated IPF-LC patients regardless of age, sex,
histologic type, and/or disease stage (pathologic stage
IeIIIA). The 5-year survival rate in our study was 37.5% for
IPF-LC patients and 72.5% for those with lung cancer only.
Such a result was in good agreement with those of previous
studies [7,8,14,15]. Furthermore, relapse-free survival
duration was also significantly shorter in our IPF-LC pa-
tients. Although cancer relapse was mentioned in 2 previ-
ous Japanese studies, they reported different results
[7,15]. Because co-variables were adjusted in our study
and stage-specific analysis was performed, we believe that
our findings are more reliable with IPF exerting indepen-
dent impact on both the survival and relapse of lung
cancer.
The incidence of respiratory death (death due to
pneumonia, ARDS, or AEIPF) was significantly higher in IPF-
LC patients than in those with lung cancer only, whereas
the cancer-related death rate was comparable between
the two groups. Such a result indicated that the reduced
survival in IPF-LC patients was mainly the consequence of
IPF.
To investigate the risk factors for respiratory death, we
compared survivors and patients with respiratory death in
IPF-LC. However, there were no differences in smoking
status, baseline pulmonary function and the characteristics
of lung cancers. It is consistent with the results of previous
study that showed patients’ factors were not significant risk
factor for postoperative pulmonary complications in pa-
tients with interstitial lung disease [18].
The present study has several limitations. First, it was a
retrospective single-institution study, and the sample size
was small. Therefore, this study may have various sources
of bias that might not have been identified and controlled.
Second, the number of patients at stage II or III was rela-
tively smaller than that of stage I patients. Thus, our results
might not be applicable for all patients with surgically
resectable lung cancer and IPF, especially those at stages II
and III. Third, according to the FEV1/FVC ratios, some IPF-
LC patients also had COPD, which might have affected
our results. However, contribution of emphysema compo-
nent to the risk of lung cancer and death might be negli-
gible in IPF-LC according to the recent study [19]. Finally,
we did not include the survival rates of patients without
surgery for comparison. Accordingly, the effects of IPF in
patients with advanced lung cancer were not fully deter-
mined. Future prospective studies with a larger sample size
are needed to confirm our results and clarify the
uncertainty.
In conclusion, our findings suggested that IPF reduced
the survival of surgically treated lung cancer patients,
regardless of age, sex, pathologic type, and/or disease
stage of lung cancer. Additionally, the distribution of lung
cancer histologic types and tumor location in IPF-LC pa-
tients might differ from that in the general population.Funding information
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